Medicenna says new bizaxofusp survival data in recurrent glioblastoma set for SNO 2026 oral presentation
Medicenna flagged new survival analysis for bizaxofusp in unresectable IDH-wildtype recurrent glioblastoma selected for an oral presentation. Results have not been presented yet; the readout is scheduled for Nov. 13, 2026 at the Society for Neuro-Oncology annual meeting. Analysis compares outcomes to an external contro